A retrospective analysis on biochemical parameters, cardiovascular risk and cardiomyopathy in elderly acromegalic patients

Journal of Endocrinological Investigation

Volumn 30, Issue 6, 2007, Pages 497-506

  Colao, A ^a   Pivonello, R ^a   Spinelli, L ^a   Galderisi, M ^a   Auriemma, R S ^a   Galdiero, M ^a   Vitale, G ^a,b   De Leo, M ^a   Lombardi, G ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Acromegaly; Cardiomyopathy; GH; IGF I; Lanreotide; Octreotide; Somatostatin; Surgery

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIHYPERTENSIVE AGENT; CORTICOTROPIN; DIGITALIS; GLUCOSE; GROWTH HORMONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LEVOTHYROXINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; SOMATOMEDIN C; TRIACYLGLYCEROL;

ACROMEGALY; ADULT; AGED; ARTHROPATHY; ARTICLE; CARDIOMYOPATHY; CARDIOVASCULAR RISK; CLINICAL FEATURE; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DIASTOLIC DYSFUNCTION; DISEASE PREDISPOSITION; DISEASE SEVERITY; FEMALE; GLUCOSE BLOOD LEVEL; GOITER; GROWTH HORMONE BLOOD LEVEL; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART RATE; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; HYPERTENSION; HYPOPHYSIS ADENOMA; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PANCREAS ISLET BETA CELL; PREVALENCE; RETROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; SYSTOLIC DYSFUNCTION;

EID: 34848813144     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03346334     Document Type: Article

References (43)

1. Colao A, Lombardi G. Growth-hormone and prolactin excess. Lancet 1998, 352: 1455-61.
2. Holdaway IM, Rajasoorya C. Epidemiology of acromegaly, Pituitary 1999, 2: 29-41.
3. Alexander L, Appleton D, Hall R, Ross WM, Wilkinson R. Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol (Oxf) 1980, 12: 71-9.
4. Bengtsson B, Eden S, Ernest I, Oden A, Sjogren B. Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand 1988, 223: 327-35.
5. Orme SM, McNally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. The United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 1998, 83: 2730-4.
6. Swearingen B, Barker FG 2nd, Katznelson L, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998, 83: 3419-26.
7. Beauregard C, Truong U, Hardy J, Serri O. Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol (Oxf) 2003, 58: 86-91.
8. Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004, 89: 667-74.
9. Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS. Growth Hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 2004, 89: 1613-7.
10. Kauppinen-Makelin R, Sane T, Reunanen A, et al. A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab 2005, 90: 4081-6.
11. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 2004, 25: 102-52.
12. Minniti G, Esposito V, Piccirilli M, Fratticci A, Santoro A, Jaffrain-Rea ML. Diagnosis and management of pituitary tumours in the elderly: a review based on personal experience and evidence of literature. Eur J Endocrinol 2005, 153: 723-35.
13. Colao A, Spiezia S, Di Somma C, et al. Circulating insulin-like growth factor-I levels are correlated with the atherosclerotic profile in healthy subjects independently of age. J Endocrinol Invest 2005, 28: 440-8.
14. Castelli WP. Lipid, risk factors and ischaemic heart disease. Atherosclerosis 1996, 124 (Suppl): S1-9.
15. Grundy SM, Cleeman JI, Bairey Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004, 110: 227-39.
16. American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2006, 29: S43-8.
17. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28: 412-9.
18. Vitale G, Pivonello R, Auriemma RS, et al. Hypertension in acromegaly and in the normal population: prevalence and determinants. Clin Endocrinol (Oxf) 2005, 63: 470-6.
19. The seventh report of the joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. JAMA 2003, 289: 2560-1.
20. Colao A, Marzullo P, Ferone D, et al. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly. J Clin Endocrinol Metab 2000, 85: 3132-40.
21. Colao A, Spinelli L, Cuocolo A, et al. Cardiovascular consequences of early-onset growth hormone excess. J Clin Endocrinol Metab 2002, 87: 3097-104.
22. Colao A, Marzullo P, Cuocolo A, et al. Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide. Clin Endocrinol (Oxf) 2003, 58: 169-76.
23. Sahn DJ, De Maria A, Kissio J, Weyman A. The committee an M-mode standardization of the American Society of Echocardiography. Recommendations regarding quantification in M-mode echocardiography: results of a survey of echocardiography measurements. Circulation 1978, 58: 1072-83.
24. Devereux RB. Detection of left ventricular hypertrophy by M-mode echocardiography. Anatomic validation, standardization and comparison to the other methods. Hypertension 1987, 9 (Suppl 2): 19-26.
25. Colao A, Ferone D, Marzullo P, et al. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 2001, 86: 2779-86.
26. Colao A, Pivonello R, Cappabianca P, et al. Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly. Clin Endocrinol (Oxf) 2005, 63: 342-9.
27. Cohen DL, Bevan JS, Adams CBT. The presentation and management of pituitary tumours in the elderly. Age Ageing 1989, 18: 247-52.
28. Turner HE, Adams CB, Wass JA. Pituitary tumors in the elderly: a 20 year experience. Eur J Endocrinol 1999, 140: 383-9.
29. Benbow SJ, Foy P, Jones B, Shaw D, MacFarlane IA. Pituitary tumours presenting in the elderly: management and outcome. Clin Endocrinol (Oxf) 1997, 46: 657-60.
30. Kovacs K, Ryan N, Horvath E, Singer W, Ezrin C. Pituitary adenomas in old age. J Gerontol 1980, 35: 16-22.
31. Puchner MJ, Knappe UJ, Ludecke DK. Pituitary surgery in elderly patients with acromegaly. Neurosurgery 1995, 36: 677-84.
32. Minniti G, Jaffrain-Rea ML, Esposito V, et al. Surgical treatment and clinical outcome of GH-secreting adenomas in elderly patients. Acta Neurochir (Wien) 2001, 143: 1205-11.
33. Gasperi M, Martino E, Manetti L, et al. Prevalence of thyroid diseases in patients with acromegaly: results of an Italian multi-center study. J Endocrinol Invest 2002, 25: 240-5.
34. Harman SM, Metter EJ, Tobin JD, et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Stud of Aging. J Clin Endocrinol Metab 2001, 86: 724-31.
35. Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 2002, 87: 589-98.
36. Desailloud R, Crépin-Hemon S, Simovic-Corroyer B. Acromegaly in elderly people. Ann Endocrinol (Paris) 2005, 66: 540-4.
37. van der Lely AJ, Harris AG, Lamberts SW. The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex. Clin Endocrinol (Oxf) 1992, 37: 181-5.
38. Colao A, Amato G, Pedroncelli AM, et al. Gender- and age-related difference in the endocrine parameters of acromegaly. J Endocrinol Invest 2002, 25: 532-8.
39. Colao A, Pivonello R, Auriemma RS, et al. Predictors of tumor shrinkage after primary therapy with somatostatin analogues in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab 2006, 91: 2112-8.
40. Parkinson C, Ryder WD, Trainer PJ, Sensus Acromegaly Study Group. The relationship between serum GH and serum IGF-I in acromegaly is gender-specific. J Clin Endocrinol Metab 2001, 86: 5240-4.
41. Edén Engström B, Burman P, Karlsson FA. Men with acromegaly need higher doses of octreotide than women. Clin Endocrinol (Oxf) 2002, 56: 73-7.
42. Bayes-Genis A, Conover CA, Schwartz RS. The Insulin-Like Growth Factor Axis. A review of atherosclerosis and restenosis. Circ Res 2000, 86: 125-30.
43. Luft R, Cerasi E, Hamberger CA. Studies on the pathogenesis of diabetes in acromegaly. Acta Endocrinol (Copenh) 1967, 56: 593-607.